Search Results - "Negrier, S"

A phase I II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer by Rossi, J-F, Négrier, S, James, N D, Kocak, I, Hawkins, R, Davis, H, Prabhakar, U, Qin, X, Mulders, P, Berns, B

“…Background: Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb…”
Get full text

Uveal melanoma: In the era of new treatments by Wespiser, M., Neidhardt, E., Negrier, S.

“…•Uveal melanoma is the most common intraocular tumor in adults worldwide.•One patient out of two recurs at a distance with the development of metastases,…”
Get full text

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma by Patil, S., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Négrier, S., Kim, S.T., Huang, X., Motzer, R.J.

“…Analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) was performed using final data from a randomized phase III trial…”
Get full text

TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma by Albiges, L., Barthélémy, P., Gross-Goupil, M., Negrier, S., Needle, M.N., Escudier, B.

“…Treatment with tivozanib, a highly selective and potent vascular endothelial growth factor receptor tyrosine kinase inhibitor, has demonstrated single-agent…”
Get full text

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib by Beuselinck, B, Karadimou, A, Lambrechts, D, Claes, B, Wolter, P, Couchy, G, Berkers, J, Paridaens, R, Schöffski, P, Méjean, A, Verkarre, V, Lerut, E, de la Taille, A, Tourani, J-M, Bigot, P, Linassier, C, Négrier, S, Berger, J, Patard, J-J, Zucman-Rossi, J, Oudard, S

“…Background: There are no validated markers that predict response in metastatic renal cell cancer (RCC) patients treated with sunitinib. We aim to study the…”
Get full text

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? by Figlin, R.A., Leibovich, B.C., Stewart, G.D., Negrier, S.

“…The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the…”
Get full text

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings by Beck, J., Procopio, G., Bajetta, E., Keilholz, U., Negrier, S., Szczylik, C., Bokemeyer, C., Bracarda, S., Richel, D.J., Staehler, M., Strauss, U.P., Mersmann, S., Burock, K., Escudier, B.

“…The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study provided sorafenib to advanced renal cell carcinoma (RCC) patients in…”
Get full text

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial by Leyvraz, S., Piperno-Neumann, S., Suciu, S., Baurain, J.F., Zdzienicki, M., Testori, A., Marshall, E., Scheulen, M., Jouary, T., Negrier, S., Vermorken, J.B., Kaempgen, E., Durando, X., Schadendorf, D., Gurunath, R. Karra, Keilholz, U.

“…In uveal melanoma (UM) with metastatic disease limited to the liver, the effect of an intrahepatic treatment on survival is unknown. We investigated…”
Get full text

TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) by Barthelemy, P., Escudier, B., Ravaud, A., Negrier, S., Needle, M.N., Albiges, L.

Get full text

Sequential sorafenib and sunitinib for renal cell carcinoma by Sablin, M P, Negrier, S, Ravaud, A, Oudard, S, Balleyguier, C, Gautier, J, Celier, C, Medioni, J, Escudier, B

“…Sorafenib and sunitinib are 2 tyrosine kinase inhibitors that were recently approved for renal cell carcinoma. In many patients sequential administration of…”
Get more information

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma by Négrier, S, Bushmakin, A.G, Cappelleri, J.C, Korytowsky, B, Sandin, R, Charbonneau, C, Michaelson, M.D, Figlin, R.A, Motzer, R.J

“…Abstract Background To determine suitability of progression-free survival (PFS) as a surrogate end-point for overall survival (OS), we evaluated the…”
Get full text

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial by Gross-Goupil, M, Fourcade, A, Blot, E, Penel, N, Négrier, S, Culine, S, Chaigneau, L, Lesimple, T, Priou, F, Lortholary, A, Kaminsky, M.C, Provencal, J, Voog, E, Bouzy, J, Laplanche, A, Fizazi, K

“…Abstract Purpose To compare the overall survival rates of good-prognosis carcinomas of an unknown primary site (CUPS) patients treated with cisplatin alone (C)…”
Get full text

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab Avastin treatment: the role of CXCL cytokines by Grepin, R, Guyot, M, Jacquin, M, Durivault, J, Chamorey, E, Sudaka, A, Serdjebi, C, Lacarelle, B, Scoazec, J-Y, Negrier, S, Simonnet, H, Pages, G

“…The anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treating renal cell carcinomas (RCCs). Although BVZ increases the progression-free…”
Get full text

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) by Motzer, R.J., Penkov, K., Haanen, J.B.A.G., Rini, B.I., Albiges, L., Campbell, M.T., Kollmannsberger, C.K., Negrier, S., Uemura, M., Lee, J.L., Gurney, H., Berger, R., Schmidinger, M., Larkin, J., Atkins, M.B., Wang, J., Robbins, P.B., Chudnovsky, A., Di Pietro, A., Choueiri, T.K.

Get full text

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial by Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Negrier, S., Chevreau, C.M., Joly, F., Geoffrois, L., Ladoire, S., Mahammedi, H., Tantot, F., Escudier, B., Albiges, L.

Get full text

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

Get full text

ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma by Ascierto, P.A., Arenberger, P., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H.M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S., Diab, A.

Get full text

Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap) by Negrier, S., Rioux-Leclercq, N., Ravaud, A., Gravis, G., Geoffrois, L., Chevreau, C.M., Rolland, F., Blanc, E., Segura-Ferlay, C., Perol, D., Gross Goupil, M., Dermeche, S., Flechon, A., Albiges, L., Escudier, B.

Get full text

2591 Surgical resection of brain metastasis from renal cancer: Is it worth it? The experience of a French Cancer Center by Eberst, L, Flechon, A, Negrier, S, Neidhardt, E.M, Jouanneau, E, Moriceau, G, Boyle, H.J

Get full text

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α by Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J

“…Background: In a randomised phase III trial of treatment-naive patients with metastatic renal cell carcinoma, sunitinib showed significant improvement in…”
Get full text